Find A LAP-BAND® System Specialist Near You

Find A LAP-BAND® System Specialist By Name

Please enter the last name of the surgeon, or the name of the practice that you are interested in learning about. (Please enter only the last name. For example, for Dr. John Doe, enter only Doe.)

LAP-BAND® System Specialist Name:Practice Name:

Note: Names and details are provided for your information only. Decisions regarding choice of surgeon and treatment options are a patient's responsibility, as is all communication and interaction with listed medical professionals. Any information you send to a surgeon is not covered by our Privacy Policy.

Identifying a LAP-BAND® Patient

Talking to patients who are dealing with obesity about weight loss and bariatric surgery isn't easy. Many of them have been struggling to manage their weight for years, if not most of their lives. For these patients, working together to be more aggressive in managing their weight could help them achieve the weight-loss they need and may help improve their overall health and obesity-related conditions.1-4

Let them know that weight loss surgery can be a proven option for obese patients whose weight is affecting their health and who have tried other methods of weight loss without success. Help your patients find a qualified LAP-BAND® specialist.

Treat obesity to improve overall health

For many obese patients, a combination of lifestyle changes and medication at best achieve a 5% to 10% loss in body weight—often insufficient to improve such obesity-related conditions as type 2 diabetes²

Bariatric surgery has been shown to provide substantial and sustainable weight loss in appropriate obese patients5-7

The lap-band AP® system is the only fda-approved lagb* for patients with bmi ≥30 and ≥1 obesity-related comorbidity or bmi ≥40

BMI 25+

Diet

Exercise

Behavior Modification

5-10% TWL (total weight loss) on average

BMI 27+

Diet

Exercise

Behavior Modification

5-10% TWL on average

BMI 35+

46% EWL at 1 year (N=371) and 52% EWL at 2 years (N=159) in severely obese patients.*

BMI 30-40

Data from the Allergan LBMI Pivotal Study shows 65% EWL and 18% TWL at 1 year (N=143) and 70% EWL and 20% TWL at 2 years (N=128) in obese patients.†

BMI 40+

34.5% EWL at 1 year (N=233) and 37.8% EWL at 2 years (N=189) in morbidly obese patients.‡ 55% to 58% EWL at 5-year follow-up for LAGB (N=640) and RYGB (N=176), respectively, in one review.

Excess Weight Loss (EWL) Defined

The % of a patient's excess weight (the difference between starting weight and ideal weight) lost

Total Weight Loss is the measure typically used in pharmaceutical and behavior modification studies.

* Data based on interim analysis of ongoing LAP-BAND AP® trial.

† Year-1 data from Allergan’s LBMI pivotal study is based on a complete database of 143 obese adults with a Month-12 visit. The currently available Year-2 results are based on a database snapshot of an incomplete data set that has not been source verified. These data were reviewed by FDA in support of the recently approved LAP-BAND® label expansion in the United States.

‡ The LAP-BAND® System was approved in the United States on the basis of a nonrandomized, single-arm study (N=299). Significant improvement in percent of excess weight loss vs baseline was achieved at 12 months (34.5%), 24 months (37.8%), and 36 months (36.2%).

§ From a systematic review of medium-term weight loss after bariatric operations. Mean % EWL for LAGB includes patients after LAP-BAND® (n=272) and other commercially available systems (n=368).7

Use LAP-BAND® System patient education materials to assess willingness

✔ Are aware of and accept the operative risks

The LAP-BAND AP® system is contraindicated for patients who5:

Are younger than 18 years.

Have conditions that may make the risk of surgery greater than the benefits.

Are unwilling or unable to comply with the required lifelong dietary, exercise, and medical requirements

Are currently or may become pregnant.

Have an inflammatory disease or condition of the gastrointestinal tract, such as ulcers, severe esophagitis, or Crohn's disease.

Have severe heart or lung disease, or any other disease that makes you a poor candidate for any surgery.

Have a problem that could cause bleeding in the esophagus or stomach. That might include esophageal or gastric varices (dilated veins). It might also be something such as congenital or acquired intestinal telangiectasia (dilation of a small blood vessel).

Have portal hypertension.

Have an abnormal esophagus, stomach, or intestine (congenital or acquired). For instance, your patient might have a narrowed opening.

Have/experienced an intraoperative gastric injury, such as a gastric perforation at or near the location of the intended band placement.

Have cirrhosis.

Have chronic pancreatitis.

Are addicted to alcohol or drugs.

Have an infection anywhere in their body, or one that could contaminate the surgical area.

Are on chronic, long-term steroid treatment.

Might be allergic to materials in the device.

Cannot tolerate pain from an implanted device.

Has an autoimmune connective tissue disease, such as systemic lupus erythematosus or scleroderma, or someone in your patient's family has one of these diseases. The same is true if your patient has symptoms of one of these diseases.

Search for a LAP-BAND® Specialist near you

Have a question? Need more information? 1-800-LAP-BAND The LAP-BAND® System Information Hotline is available 7 days a week.

Important LAP-BAND® System Safety Information

Indications: The LAP-BAND® System is indicated for weight reduction for patients with obesity, with a Body Mass Index (BMI) of at least 40 kg/m2 or a BMI of at least 30 kg/m2 with one or more obesity-related comorbid conditions.

It is indicated for use only in adult patients who have failed more conservative weight reduction alternatives, such as supervised diet, exercise and behavior modification programs. Patients who elect to have this surgery must make the commitment to accept significant changes in their eating habits for the rest of their lives.

Contraindications: The LAP-BAND® System is not recommended for non-adult patients, patients with conditions that may make them poor surgical candidates or increase the risk of poor results (e.g., inflammatory or cardiopulmonary diseases, GI conditions, symptoms or family history of autoimmune disease, cirrhosis), who are unwilling or unable to comply with the required dietary restrictions, who have alcohol or drug addictions, or who currently are or may be pregnant.

Warnings: The LAP-BAND® System is a long-term implant. Explant and replacement surgery may be required. Patients who become pregnant or severely ill, or who require more extensive nutrition may require deflation of their bands. Anti-inflammatory agents, such as aspirin, should be used with caution and may contribute to an increased risk of band erosion.

Adverse Events: Placement of the LAP-BAND® System is major surgery and, as with any surgery, death can occur. Possible complications include the risks associated with the medications and methods used during surgery, the risks associated with any surgical procedure, and the patient's ability to tolerate a foreign object implanted in the body.

Band slippage, erosion and deflation, reflux, obstruction of the stomach, dilation of the esophagus, infection, or nausea and vomiting may occur. Reoperation may be required.

Rapid weight loss may result in complications that may require additional surgery. Deflation of the band may alleviate excessively rapid weight loss or esophageal dilation.

Important: For full safety information please click here, talk with your doctor, or call Apollo Customer Support at 1-855-551-3123.